CN107743491B - 用于治疗和预防病毒感染的新的氧硫杂环戊烷甲酸及其衍生物 - Google Patents

用于治疗和预防病毒感染的新的氧硫杂环戊烷甲酸及其衍生物 Download PDF

Info

Publication number
CN107743491B
CN107743491B CN201680026218.1A CN201680026218A CN107743491B CN 107743491 B CN107743491 B CN 107743491B CN 201680026218 A CN201680026218 A CN 201680026218A CN 107743491 B CN107743491 B CN 107743491B
Authority
CN
China
Prior art keywords
amino
thiazolo
pyrimidin
compound
oxathiolan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680026218.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN107743491A (zh
Inventor
刘海侠
吴国龙
贠红英
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN107743491A publication Critical patent/CN107743491A/zh
Application granted granted Critical
Publication of CN107743491B publication Critical patent/CN107743491B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201680026218.1A 2015-05-08 2016-05-04 用于治疗和预防病毒感染的新的氧硫杂环戊烷甲酸及其衍生物 Expired - Fee Related CN107743491B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2015/078578 2015-05-08
CN2015078578 2015-05-08
PCT/EP2016/059949 WO2016180691A1 (en) 2015-05-08 2016-05-04 Novel oxathiolane carboxylic acids and derivatives for the treatment and prophylaxis of virus infection

Publications (2)

Publication Number Publication Date
CN107743491A CN107743491A (zh) 2018-02-27
CN107743491B true CN107743491B (zh) 2020-08-21

Family

ID=55910268

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680026218.1A Expired - Fee Related CN107743491B (zh) 2015-05-08 2016-05-04 用于治疗和预防病毒感染的新的氧硫杂环戊烷甲酸及其衍生物

Country Status (5)

Country Link
US (1) US10183954B2 (enExample)
EP (1) EP3294745B1 (enExample)
JP (1) JP6779232B2 (enExample)
CN (1) CN107743491B (enExample)
WO (1) WO2016180691A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021009496A (es) 2019-02-08 2021-09-08 Progeneer Inc Complejo de colesterol-agonista del receptor 7 u 8 tipo larga distancia, y uso del mismo.
EP4115901A4 (en) 2020-03-02 2024-04-10 Progeneer Inc. Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
US20230277525A1 (en) 2020-08-04 2023-09-07 Progeneer Inc Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof
WO2022031011A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적으로 작용하는 아주번트 앙상블
WO2022031021A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적 제어가 가능한 아주번트를 포함하는 mrna 백신

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
CN101193898A (zh) * 2005-04-06 2008-06-04 阿斯利康(瑞典)有限公司 新颖的5,7-二取代的[1,3]噻唑并[4,5-d]嘧啶-2(3H)-酮衍生物
CN101212968A (zh) * 2004-12-17 2008-07-02 安那迪斯药品股份有限公司 3,5-二取代的和3,5,7-三取代的-3H-噁唑并以及3H-噻唑并[4,5-d]嘧啶-2-酮化合物及其前药
CN103930426A (zh) * 2011-11-08 2014-07-16 霍夫曼-拉罗奇有限公司 作为大麻素受体2激动剂的[1，2，3]三唑并[4，5-d]嘧啶衍生物
CN104230952A (zh) * 2014-08-16 2014-12-24 沈阳药科大学 含有嘧啶骨架的化合物及其制备方法和用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476659A (en) 1982-11-09 1995-12-19 The Scripps Research Institute Cancerous B cell treatment using substituted nucleoside derivatives
US5166141A (en) 1983-11-01 1992-11-24 Scripps Clinic And Research Foundation Immunostimulating 7-deaza-7-oxa- and 7-deaza-7-oxo-analogs of 8-substituted-guanine-9-(1'-beta-D-aldoglycosidyl) derivatives and methods of treating test animals
US5041426A (en) 1987-12-21 1991-08-20 Brigham Young University Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides
EP1072607A3 (en) 1996-10-16 2001-09-12 ICN Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses therof
DE69729887T2 (de) 1996-10-16 2005-07-28 ICN Pharmaceuticals, Inc., Costa Mesa Purin-L-Nukleoside, Analoga und deren Verwendung
EP1124562B1 (en) * 1998-11-02 2005-01-19 Gilead Sciences, Inc. Combination therapy to treat hepatitis b virus
KR20090089922A (ko) * 2000-10-18 2009-08-24 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
WO2003020222A2 (en) * 2001-09-04 2003-03-13 Merck & Co., Inc. PYRROLO[2,3-d]PYRIMIDINES FOR INHIBITING RNA-DEPENDENT RNA VIRAL POLYMERASE
US20050004144A1 (en) 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
ES2342069T4 (es) 2003-09-05 2011-01-26 Anadys Pharmaceuticals, Inc. Ligandos de tlr7 para el tratamiento de la hepatitis c.
EP1824482B1 (en) 2004-12-17 2014-02-12 Anadys Pharmaceuticals, Inc. 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
AR061024A1 (es) 2006-05-22 2008-07-30 Novartis Ag Maleato de 5-amino-3- (2'3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d] pirimidin-2-ona.
US7709448B2 (en) 2006-06-22 2010-05-04 Anadys Pharmaceuticals, Inc. Prodrugs of 5-amino-3-(3′-deoxy-β-D-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione
US7528115B2 (en) 2006-07-18 2009-05-05 Anadys Pharmaceuticals, Inc. Carbonate and carbamate prodrugs of thiazolo[4,5-d]pyrimidines
BRPI0717741A2 (pt) 2006-10-17 2014-04-08 Anadys Pharmaceuticals Inc Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença
US20110166092A1 (en) 2007-08-20 2011-07-07 Anadys Pharmaceuticals, Inc. Dosing methods for treating disease
JP2017531655A (ja) * 2014-10-11 2017-10-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 感染性疾患の処置に使用するための化合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
CN101212968A (zh) * 2004-12-17 2008-07-02 安那迪斯药品股份有限公司 3,5-二取代的和3,5,7-三取代的-3H-噁唑并以及3H-噻唑并[4,5-d]嘧啶-2-酮化合物及其前药
CN101193898A (zh) * 2005-04-06 2008-06-04 阿斯利康(瑞典)有限公司 新颖的5,7-二取代的[1,3]噻唑并[4,5-d]嘧啶-2(3H)-酮衍生物
CN103930426A (zh) * 2011-11-08 2014-07-16 霍夫曼-拉罗奇有限公司 作为大麻素受体2激动剂的[1，2，3]三唑并[4，5-d]嘧啶衍生物
CN104230952A (zh) * 2014-08-16 2014-12-24 沈阳药科大学 含有嘧啶骨架的化合物及其制备方法和用途

Also Published As

Publication number Publication date
US20180065991A1 (en) 2018-03-08
WO2016180691A1 (en) 2016-11-17
JP2018515503A (ja) 2018-06-14
EP3294745B1 (en) 2020-01-01
US10183954B2 (en) 2019-01-22
JP6779232B2 (ja) 2020-11-04
EP3294745A1 (en) 2018-03-21
CN107743491A (zh) 2018-02-27
HK1250709A1 (zh) 2019-01-11

Similar Documents

Publication Publication Date Title
US11130758B2 (en) Tetrahydropyrazolopyrimidine compounds
JP6806709B2 (ja) ウイルス感染症の治療と予防のための新規置換アミノチアゾロピリミジンジオン
CN107820498B (zh) 用于治疗和预防病毒感染的取代的氨基噻唑并嘧啶二酮
AU2018264036A1 (en) Selectively substituted quinoline compounds
CN107743491B (zh) 用于治疗和预防病毒感染的新的氧硫杂环戊烷甲酸及其衍生物
JP2019516714A (ja) 感染症の治療のための酸素、硫黄および窒素リンカーを有する新規ピラジン化合物
CN110088104A (zh) 用于治疗和预防乙型肝炎病毒感染的新的四氢吡啶并嘧啶化合物
HK1250709B (zh) 用於治疗和预防病毒感染的新的氧硫杂环戊烷甲酸及其衍生物
JP7328977B2 (ja) ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体
HK1248711B (zh) 用於治疗和预防病毒感染的新的取代的氨基噻唑并嘧啶二酮
HK40011887B (zh) 用於治疗和预防乙型肝炎病毒感染的四氢吡啶并嘧啶化合物
HK1251554B (zh) 用於治疗和预防病毒感染的取代的氨基噻唑并嘧啶二酮
HK1203498B (en) Tetrahydropyrazolopyrimidine compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1250709

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200821

CF01 Termination of patent right due to non-payment of annual fee